1.Alternative Name：c-MET
2.Target：HGFR
3.Source：Human HGFR was expressed from HEK293 with poly His at the C-terminal
4.Sequence：Glu25-Thr932
5.Protein structure:P08581His
6.Molecular Characterization:The protein has a calculated MW of 106kDa.The reducing (R) heterodimer protein migrates as 80-100 kDa due to glycosylation
7.Purity:SDS-PAGE>90%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 95%.

13.ELISA

When Recombinant Human HGFR(c-MET)/His Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human MET(Emibetuzumab) that produces 50% of the optimal binding response is approximately 60 ng/ml.

14.SPR

Abti-Human EGFRxMET(Amivantamab)（Cat.No.B976401）captured on Protein A chip , can bind Recombinant Human HGFR(c-MET)/His Protein（Cat.No.B22160812） with a KD constant of 4.17E-10 M, determined in a SPR assay .

Note：For research use only .